<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01894594</url>
  </required_header>
  <id_info>
    <org_study_id>09-12-13</org_study_id>
    <nct_id>NCT01894594</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease</brief_title>
  <official_title>Alkali Therapy in Subjects With Sickle Cell Disease (SCD) - Evaluation of Efficacy, Safety, and Beneficial Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Case Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Case Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effect of alkali administration on bicarbonate
      and potassium levels in patients with Sickle Cell Disease (SCD) and depressed serum
      bicarbonate levels. The study is a prospective non-blinded evaluation of tolerability and
      efficacy of alkali repletion with 4 weeks of observation and two sequential 4 week courses
      of escalating oral sodium bicarbonate treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum bicarbonate level</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the effect of alkali administration on bicarbonate and potassium levels in patients with SCD and depressed serum bicarbonate levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemolysis markers</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the effect of alkali administration on improvement in hemolysis and on sequelae of impaired kidney function, ie, LDH, Hgb, reticulocyte count, red cell half-life, and muscle strength, Vitamin D levels, and  markers of bone turnover, respectively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tubular effect</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the influence of alkali administrations on markers of kidney tubule inflammation.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Metabolic Acidosis</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and dose will be increased after evaluation every 4 weeks.
Weekly schedule:
0-4 weeks: Serial Measurement at baseline, without therapy
4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing
8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing
to the closest dose of 650 mg (7.74 mEq)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sickle cell patients with HbSS.

          -  eGFR &lt;90 ml/min/1.73m2(determined by abbreviated 4 variable modification MDRD
             equation) and/or measured urinary albumin to creatinine ratio &gt; 30mg/g.

          -  Age â‰¥18 years

        Exclusion Criteria:

          -  Previous chronic treatment with alkali (including sodium bicarbonate, calcium
             carbonate or baking soda)

          -  Bicarbonate level &gt;25 mEq/L

          -  Decompensated heart failure

          -  Uncontrolled systolic blood pressure &gt;140 mm/Hg (the cutoff for systolic hypertension
             in SCD is lower than in non-SCD)

          -  Moderate-to-severe lower extremity edema

          -  Projected progression to ESRD within 6 months

          -  Kidney transplantation

          -  VOC within 1 week of study entry

          -  Active (open) leg ulcer

          -  Change in hydroxyurea dose within the last 3 months, unless a self-limited
             interruption of a stable dose

          -  Blood transfusion within 8 weeks, unless on chronic transfusions Pregnancy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Little, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Case Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Little, MD</last_name>
    <phone>216-844-5868</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Little, MD</last_name>
      <phone>216-844-5868</phone>
    </contact>
    <investigator>
      <last_name>Jane Little, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Case Medical Center</investigator_affiliation>
    <investigator_full_name>Jane Little</investigator_full_name>
    <investigator_title>Director, Sickle cell disease program</investigator_title>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Bicarbonate therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
